These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27795906)

  • 1. Pilot-testing an adverse drug event reporting form prior to its implementation in an electronic health record.
    Chruscicki A; Badke K; Peddie D; Small S; Balka E; Hohl CM
    Springerplus; 2016; 5(1):1764. PubMed ID: 27795906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing an Adverse Drug Event Reporting System to Prevent Unintentional Reexposures to Harmful Drugs: Study Protocol for a Multiple Methods Design.
    Peddie D; Small SS; Badke K; Wickham ME; Bailey C; Chruscicki A; Ackerley C; Balka E; Hohl CM
    JMIR Res Protoc; 2016 Aug; 5(3):e169. PubMed ID: 27538362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Drug Event Reporting From Clinical Care: Mixed-Methods Analysis for a Minimum Required Dataset.
    Peddie D; Small SS; Badke K; Bailey C; Balka E; Hohl CM
    JMIR Med Inform; 2018 Jun; 6(2):e10248. PubMed ID: 29954724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals.
    Stergiopoulos S; Brown CA; Felix T; Grampp G; Getz KA
    Drug Saf; 2016 Nov; 39(11):1117-1127. PubMed ID: 27638657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach.
    Mirbaha F; Shalviri G; Yazdizadeh B; Gholami K; Majdzadeh R
    Implement Sci; 2015 Aug; 10():110. PubMed ID: 26250159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report.
    Jha AK; Kuperman GJ; Teich JM; Leape L; Shea B; Rittenberg E; Burdick E; Seger DL; Vander Vliet M; Bates DW
    J Am Med Inform Assoc; 1998; 5(3):305-14. PubMed ID: 9609500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Root Cause Analysis of Ambulatory Adverse Drug Events That Present to the Emergency Department.
    Gertler SA; Coralic Z; López A; Stein JC; Sarkar U
    J Patient Saf; 2016 Sep; 12(3):119-24. PubMed ID: 24583958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot testing of checklists to discern adverse drug reactions and adverse drug events.
    Chen AM; Kiersma ME; Shepler BM; Murawski MM
    J Am Pharm Assoc (2003); 2013; 53(1):61-9. PubMed ID: 23636158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extraction of Information Related to Drug Safety Surveillance From Electronic Health Record Notes: Joint Modeling of Entities and Relations Using Knowledge-Aware Neural Attentive Models.
    Dandala B; Joopudi V; Tsou CH; Liang JJ; Suryanarayanan P
    JMIR Med Inform; 2020 Jul; 8(7):e18417. PubMed ID: 32459650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacist- versus physician-initiated admission medication reconciliation: impact on adverse drug events.
    Mergenhagen KA; Blum SS; Kugler A; Livote EE; Nebeker JR; Ott MC; Signor D; Sung S; Yeh J; Boockvar KS
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):242-50. PubMed ID: 22819386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of the adverse drug event trigger tool and the global trigger tool for identifying adverse drug events: experience in a Belgian hospital.
    Carnevali L; Krug B; Amant F; Van Pee D; Gérard V; de Béthune X; Spinewine A
    Ann Pharmacother; 2013 Nov; 47(11):1414-9. PubMed ID: 24285758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting.
    Linder JA; Haas JS; Iyer A; Labuzetta MA; Ibara M; Celeste M; Getty G; Bates DW
    Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1211-5. PubMed ID: 21155192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An external facilitation intervention to increase uptake of an adverse drug event reporting intervention.
    Lau EY; Small SS; Butcher K; Cragg A; Loh GW; Shalansky S; Hohl CM
    Front Health Serv; 2023; 3():1106586. PubMed ID: 37332530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consumers' adverse drug event reporting via community pharmacists: three stakeholder perception.
    Kitisopee T; Assanee J; Sorofman BA; Watcharadmrongkun S
    J Pharm Policy Pract; 2022 Mar; 15(1):19. PubMed ID: 35287746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why Clinicians Don't Report Adverse Drug Events: Qualitative Study.
    Hohl CM; Small SS; Peddie D; Badke K; Bailey C; Balka E
    JMIR Public Health Surveill; 2018 Feb; 4(1):e21. PubMed ID: 29487041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior.
    Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M
    Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building a time-saving and adaptable tool to report adverse drug events.
    Parès Y; Declerck G; Hussain S; Ng R; Jaulent MC
    Stud Health Technol Inform; 2013; 192():903-7. PubMed ID: 23920689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validating a Framework for Coding Patient-Reported Health Information to the Medical Dictionary for Regulatory Activities Terminology: An Evaluative Study.
    Brajovic S; Blaser DA; Zisk M; Caligtan C; Okun S; Hall M; Pamer CA
    JMIR Med Inform; 2018 Aug; 6(3):e42. PubMed ID: 30131314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacist reporting of serious adverse drug events to the Food and Drug Administration.
    Gavaza P; Brown CM; Lawson KA; Rascati KL; Steinhardt M; Wilson JP
    J Am Pharm Assoc (2003); 2012; 52(5):e109-12. PubMed ID: 23023857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis.
    Wang L; Rastegar-Mojarad M; Ji Z; Liu S; Liu K; Moon S; Shen F; Wang Y; Yao L; Davis Iii JM; Liu H
    Front Pharmacol; 2018; 9():875. PubMed ID: 30131701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.